Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Tucidinostat in HR+/HER2- Advanced Breast Cancer
NCT05335473Phase 2Terminated
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in breast cancer, sponsored by Henan Cancer Hospital. Started May 2022; status: terminated.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05335473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335473.